Bystolic & Weight Loss | Healthfully

Bystolic, a high blood pressure medication, has been demonstrated to have a modest effect on weight loss. However, to date, only one study has demonstrated this effect, and if weight loss is truly your goal, a healthful diet and exercise are likely to be more effective.

About Bystolic

Bystolic, or nebivolol, is a type of drug known as a beta-blocker. It binds to beta-1 receptors on heart muscle and causes a decrease in blood pressure. It also has the rare ability to dilate blood vessels because of its effects mediated by increased nitric oxide production, a vasodilatory chemical, according to Thomas and David Westfall in “Goodman and Gilman’s Pharmacology.”

Beta Blockers and Weight Gain

Concerta & Weight Loss

Learn More

According to Dr. Sheldon Sheps, who writes for the Mayo Clinic, most beta blockers tend to cause weight gain — not loss 2. This is particularly the case with older beta blockers, including metoprolol and atenolol. The average weight gain is not dramatic — usually less than 4 lb. — but doctors don’t necessarily understand why it occurs. Sheps says it could either be due to metabolic slowing as a result of the beta blocker, or of increased water retention, particularly if you discontinued a diuretic to start the beta blocker.

• According to Dr. Sheldon Sheps, who writes for the Mayo Clinic, most beta blockers tend to cause weight gain — not loss 2.

Bystolic and Weight Loss

Despite the classic association of beta blockers with weight gain, one study of Bystolic suggests that it may promote modest weight loss in some people 2. In the September 2010 issue of the Journal of Cardiovascular Pharmacology, Dennis Ladage and colleagues report the results of a study in which about 5,000 people with type 2 diabetes and high blood pressure took Bystolic during a 12-week period 3. At the end of the 12 weeks, an average weight loss of about 2 lb. was noted in study participants.

Impact of Study

Differences Between Strattera & Concerta

Learn More

Although Ladage and colleagues demonstrated a modest amount of weight loss in their population, theirs is the only study to date that examines the association between Bystolic and weight loss. Other studies need to be performed to confirm or refute its findings. As well, an approximately 2 lb. weight loss over 12 weeks is not a large weight loss. Medline Plus, a project of the National Institutes of Health, recommends a weight loss of 1 to 2 lb. per week in an individual trying to lose weight.

• Although Ladage and colleagues demonstrated a modest amount of weight loss in their population, theirs is the only study to date that examines the association between Bystolic and weight loss.

The bottom line is that Bystolic is intended to be used as a high blood pressure medication. It might have some effect on weight loss, but based on the best available data to date, it shouldn’t be relied upon as a weight loss agent. As always, the best advice for someone trying to lose weight is to eat a healthful diet and get plenty of exercise.

Effect of Third-Generation Beta Blockers on Weight Loss in a Population of Overweight-Obese Subjects in a Controlled Dietary Regimen

1. Whitlock G., Whitlock G., Lewington S., et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies.
Lancet (London, England)
. 2009;373(9669):1083–1096. doi: 10.1016/S0140-6736(09)60318-4. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

2. Gregg E. W., Cheng Y. J., Cadwell B. L., et al. Secular trends in cardiovascular disease risk factors according to body mass index in US adults.
Journal of the American Medical Association
. 2005;293(15):1868–1874. doi: 10.1001/jama.293.15.1868. [PubMed] [CrossRef] [Google Scholar]

3. Greenfield J., Campbell L. Role of the autonomic nervous system and neuropeptides in the development of obesity in humans: targets for therapy?
Current Pharmaceutical Design
. 2008;14(18):1815–1820. doi: 10.2174/138161208784746716. [PubMed] [CrossRef] [Google Scholar]

4. Bray G. A. Obesity, a disorder of nutrient partitioning: the MONA LISA hypothesis.
Journal of Nutrition
. 1991;121(8):1146–1162. doi: 10.1093/jn/121.8.1146. [PubMed] [CrossRef] [Google Scholar]

5. Bray G. A. Obesity–a state of reduced sympathetic activity and normal or high adrenal activity (the autonomic and adrenal hypothesis revisited)
International Journal of Obesity
. 1990;14(3):77–91. [PubMed] [Google Scholar]

6. Astrup A. The sympathetic nervous system as a target for intervention in obesity.
International Journal of Obesity and Related Metabolic Disorders
. 1995;19(7):S24–S28. [PubMed] [Google Scholar]

7. Macdonald I. A. Advances in our understanding of the role of the sympathetic nervous system in obesity.
International Journal of Obesity and Related Metabolic Disorders
. 1995;19(7):S2–S7. [PubMed] [Google Scholar]

8. Bachman E. S., Dhillon H., Zhang C. Y., et al. Beta AR signaling required for diet-induced thermogenesis and obesity resistance.
Science
. 2002;297(5582):843–845. doi: 10.1126/science.1073160. [PubMed] [CrossRef] [Google Scholar]

9. Lamont L. S., Brown T., Riebe D., Caldwell M. The major components of human energy balance during chronic ??-Adrenergic blockade.
Journal of Cardiopulmonary Rehabilitation
. 2000;20(4):247–250. doi: 10.1097/00008483-200007000-00006. [PubMed] [CrossRef] [Google Scholar]

10. Steinkraus V., Nose M., Scholz H., Thormählen K. Time course and extent of α1-adrenoceptor density changes in rat heart after β-adrenoceptor blockade.
British Journal of Pharmacology
. 1989;96(2):441–449. doi: 10.1111/j.1476-5381.1989.tb11836.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

11. Lee P., Kengne A.-P., Greenfield J. R., Day R. O., Chalmers J., Ho K. K. Y. Metabolic sequelae of β-blocker therapy: weighing in on the obesity epidemic?
International Journal of Obesity
. 2011;35(11):1395–1403. doi: 10.1038/ijo.2010.284. [PubMed] [CrossRef] [Google Scholar]

12. Gammone M., D’Orazio N. Anti-obesity activity of the marine carotenoid fucoxanthin.
Marine Drugs
. 2015;13(4):2196–2214. doi: 10.3390/md13042196. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

13. Fergus I. V., Connell K. L., Ferdinand K. C. A comparison of vasodilating and non-vasodilating beta-blockers and their effects on cardiometabolic risk.
Current Cardiology Reports
. 2015;17(6):p. 38. doi: 10.1007/s11886-015-0592-x. [PubMed] [CrossRef] [Google Scholar]

14. O’Sullivan A. J., Crampton L. J., Freund J., Ho K. K. The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women.
Journal of Clinical Investigation
. 1998;102:1035–1040. [PMC free article] [PubMed] [Google Scholar]

15. Marra M., Cioffi I., Sammarco R., et al. Prediction and evaluation of resting energy expenditure in a large group of obese outpatients.
International Journal of Obesity
. 2017;41(5):697–705. doi: 10.1038/ijo.2017.34. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

16. Washburn R. A., Jacobsen D. J., Sonko B. J., Hill J. O., Donnelly J. E. The validity of the Stanford seven-day Physical Activity Recall in young adults.
Medicine & Science in Sports & Exercise
. 2003;35(8):1374–1380. doi: 10.1249/01.mss.0000079081.08476.ea. [PubMed] [CrossRef] [Google Scholar]

17. Westerterp K. R. Physical activity and physical activity induced energy expenditure in humans: measurement, determinants, and effects.
Frontiers in Physiology
. 2013;4:p. 90. doi: 10.3389/fphys.2013.00090. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

18. Lafontan M., Moro C., Berlan M., Crampes F., Sengenes C., Galitzky J. Control of lipolysis by natriuretic peptides and cyclic GMP.
Trends in Endocrinology and Metabolism
. 2008;19(4):130–137. doi: 10.1016/j.tem.2007.11.006. [PubMed] [CrossRef] [Google Scholar]

19. Arner P., Kriegholm E., Engfeldt P., Bolinder J. Adrenergic regulation of lipolysis in situ at rest and during exercise.
Journal of Clinical Investigation
. 1990;85(3):893–898. doi: 10.1172/jci114516. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

20. Sharma A. M., Pischon T., Hardt S., Kunz I., Luft F. C. Hypothesis: β-adrenergic receptor blockers and weight gain.
Hypertension
. 2001;37(2):250–254. doi: 10.1161/01.hyp.37.2.250. [PubMed] [CrossRef] [Google Scholar]

21. Rossner S., Taylor C. L., Byington R. P., Furberg C. D. Long term propranolol treatment and changes in body weight after myocardial infarction.
BMJ
. 1990;300(6729):902–903. doi: 10.1136/bmj.300.6729.902. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

22. Turner R., Holman R., Stratton I., Manley S., Frighi V. Hypertension in Diabetes S. III. Hypertension in diabetes study III. Prospective study of therapy of hypertension in type 2 diabetic patients: efficacy of ACE inhibition and β-blockade.
Diabetic Medicine
. 1994;11(8):773–782. doi: 10.1111/j.1464-5491.1994.tb00352.x. [PubMed] [CrossRef] [Google Scholar]

23. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group.
BMJ
. 1998;317:713–720. [PMC free article] [PubMed] [Google Scholar]

24. Schiffrin E. L. Correction of remodeling and function of small arteries in human hypertension by cilazapril, an angiotensin I converting enzyme inhibitor.
Journal of Cardiovascular Pharmacology
. 1996;27(Suppl 2):S13–S18. doi: 10.1097/00005344-199600002-00004. [PubMed] [CrossRef] [Google Scholar]

25. Foss O. P., Jensen E. K. The effect of captopril and metoprolol as monotherapy or combined with bendroflumethiazide on blood lipids.
Journal of Internal Medicine
. 1990;227(2):119–123. doi: 10.1111/j.1365-2796.1990.tb00129.x. [PubMed] [CrossRef] [Google Scholar]

26. Wikstrand J., Warnold I., Olsson G., Tuomilehto J., Elmfeldt D., Berglund G. Primary prevention with metoprolol in patients with hypertension.
Journal of the American Medical Association
. 1988;259(13):1976–1982. doi: 10.1001/jama.1988.03720130040027. [PubMed] [CrossRef] [Google Scholar]

27. Wilhelmsen L., Berglund G. r., Elmfeldt D., et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial.
Journal of Hypertension
. 1987;5(5):561–572. doi: 10.1097/00004872-198710000-00009. [PubMed] [CrossRef] [Google Scholar]

28. The treatment of mild hypertension research group. The treatment of mild hypertension study. A randomized, placebocontrolled trial of a nutritional-hygienic regimen along with various drug monotherapies. The treatment of mild hypertension research group.
Archives of Internal Medicine
. 1991;151:1413–1423. [PubMed] [Google Scholar]

29. Davis B. R., Oberman A., Blaufox M. D., et al. Effect of antihypertensive therapy on weight loss. The trial of antihypertensive interventions and management research group.
Hypertension
. 1992;19(4):393–399. doi: 10.1161/01.hyp.19.4.393. [PubMed] [CrossRef] [Google Scholar]

30. Jéquier E., Tappy L. Regulation of body weight in humans.
Physiological Reviews
. 1999;79(2):451–480. doi: 10.1152/physrev.1999.79.2.451. [PubMed] [CrossRef] [Google Scholar]

31. Gammone M. A., Riccioni G., Massari F., D’Orazio N. Beneficial effect of ivabradine against cardiovascular diseases.
Frontiers in Bioscience
. 2020;12(1):161–172. doi: 10.2741/s545. [PubMed] [CrossRef] [Google Scholar]

32. Gammone M. A., Riccioni G., D’Orazio N. Ivabradine: a new frontier in the treatment of stable coronary artery disease and chronic heart failure.
La Clinica terapeutica
. 2020;171(5):e449–e453. doi: 10.7417/CT.2020.2256. [PubMed] [CrossRef] [Google Scholar]

33. Toblli J., DiGennaro F., Giani Jorge F., Fernando Pablo D. Nebivolol: impact on cardiac and endothelial function and clinical utility.
Vascular Health and Risk Management
. 2012:151–160. doi: 10.2147/vhrm.s20669. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

34. Taylor A. A., Bakris G. L. The role of vasodilating beta-blockers in patients with hypertension and the cardiometabolic syndrome.
The American Journal of Medicine
. 2010;123(7 Suppl 1):S21–S26. doi: 10.1016/j.amjmed.2010.04.015. [PubMed] [CrossRef] [Google Scholar]

35. Merchant N., Searles C. D., Pandian A., et al. Nebivolol in high-risk, obese African Americans with stage 1 hypertension: effects on blood pressure, vascular compliance, and endothelial function.
Journal of Clinical Hypertension
. 2009;11(12):720–725. doi: 10.1111/j.1751-7176.2009.00198.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

36. Giles T. D., Sander G. E., Nossaman B. D., Kadowitz P. J. Impaired vasodilation in the pathogenesis of hypertension: focus on nitric oxide, endothelial-derived hyperpolarizing factors, and prostaglandins.
Journal of Clinical Hypertension
. 2012;14(4):198–205. doi: 10.1111/j.1751-7176.2012.00606.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

37. Ayers K., Byrne L. M., DeMatteo A., Brown N. J. Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome.
Hypertension
. 2012;59(4):893–898. doi: 10.1161/hypertensionaha.111.189589. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

38. Kandavar R., Higashi Y., Chen W., et al. The effect of nebivolol versus metoprolol succinate extended release on asymmetric dimethylarginine in hypertension.
Journal of the American Society of Hypertension
. 2011;5(3):161–165. doi: 10.1016/j.jash.2010.11.003. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

39. Rizos C. V., Elisaf M. S. Antihypertensive drugs and glucose metabolism.
World Journal of Cardiology
. 2014;6(7):517–530. doi: 10.4330/wjc.v6.i7.517. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

40. Fonseca V., Sharma P. P., Shah M., Deedwania P. Risk of new-onset diabetes mellitus associated with beta-blocker treatment for hypertension.
Current Medical Research and Opinion
. 2011;27(4):799–807. doi: 10.1185/03007995.2011.555477. [PubMed] [CrossRef] [Google Scholar]

41. Peter P., Martin U., Sharma A., Dunne F. Effect of treatment with nebivolol on parameters of oxidative stress in type 2 diabetics with mild to moderate hypertension.
Journal of Clinical Pharmacy and Therapeutics
. 2006;31(2):153–159. doi: 10.1111/j.1365-2710.2006.00718.x. [PubMed] [CrossRef] [Google Scholar]

42. Gul R., Mahmood A., Luck C., et al. Regulation of cardiac miR-208a, an inducer of obesity, by rapamycin and nebivolol.
Obesity
. 2015;23(11):2251–2259. doi: 10.1002/oby.21227. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

43. Remme W. J., Torp-Pedersen C., Cleland J. G. F., et al. Carvedilol protects better against vascular events than metoprolol in heart failure.
Journal of the American College of Cardiology
. 2007;49(9):963–971. doi: 10.1016/j.jacc.2006.10.059. [PubMed] [CrossRef] [Google Scholar]

44. Gilbert E. M., Abraham W. T., Olsen S., et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart.
Circulation
. 1996;94(11):2817–2825. doi: 10.1161/01.cir.94.11.2817. [PubMed] [CrossRef] [Google Scholar]

45. Ladage D., Reidenbach C., Rieckeheer E., Graf C., Schwinger R. H., Brixius K. Nebivolol lowers blood pressure and increases weight loss in patients with hypertension and diabetes in regard to age.
Journal of Cardiovascular Pharmacology
. 2010;56(3):275–281. doi: 10.1097/fjc.0b013e3181eb4ff2. [PubMed] [CrossRef] [Google Scholar]

46. Bakris G. L., Fonseca V., Katholi R. E., et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension.
Journal of the American Medical Association
. 2004;292(18):2227–2236. doi: 10.1001/jama.292.18.2227. [PubMed] [CrossRef] [Google Scholar]

47. Martsevich S., Kutishenko N., Deev A., Oganov R., Shalnova S. Comparision of antyhypertensive and metabolic effects of carvedilol and metaprolol in hypertensive patients with overweight and obesity. Camellia Trial.l: pp.34.365.
Journal of Hypertension
. 2010;28 doi: 10.1097/01.hjh.0000379903.65877.a7. [CrossRef] [Google Scholar]

48. Gammone M., Riccioni G., Parrinello G., D’Orazio N. Omega-3 polyunsaturated fatty acids: benefits and endpoints in sport.
Nutrients
. 2018 Dec 27;11(1):p. 46. doi: 10.3390/nu11010046. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

49. Riccioni G., Gammone M., Currenti W., D’Orazio N. Effectiveness and safety of dietetic supplementation of a new nutraceutical on lipid profile and serum inflammation biomarkers in hypercholesterolemic patients.
Molecules
. 2018 May 14;23(5):p. 1168. doi: 10.3390/molecules23051168. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

50. Frishman W. H., Saunders E. β-Adrenergic blockers.
Journal of Clinical Hypertension
. 2011;13(9):649–653. doi: 10.1111/j.1751-7176.2011.00515.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

51. Merchant N., Rahman S. T., Ferdinand K. C., Haque T., Umpierrez G. E., Khan B. V. Effects of nebivolol in obese African Americans with hypertension (NOAAH): markers of inflammation and obesity in response to exercise-induced stress.
Journal of Human Hypertension
. 2011;25(3):196–202. doi: 10.1038/jhh.2010.39. [PubMed] [CrossRef] [Google Scholar]

52. Mancia G., The Task Force Members ESH/ESC guidelines for the management of arterial hypertension—the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
Journal of Hypertension
. 2013;31(7):1281–1357. [PubMed] [Google Scholar]

Bystolic Tablets (Nebivolol Tablets) Side Effects, Warnings, Methods of Use

• Generic Name: Nebivolol Tablets
• Brand Name: Bystolic Tablets

• Overview
• Consumer Information

9 0009 Professional Information

• Related Resources

Bystolic Tablets Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

What is bystolic?

Bystolic (nebivolol) is a beta-blocker used to treat high blood pressure (hypertension).

What are the side effects of Bystolic?

Side effects of Bystolic include:

• Headache,
• dizziness,
• fatigue,
• fatigue,

9 0009 slow heartbeat,

• nausea,
• abdominal pain,
• diarrhea,
• trouble sleeping (insomnia),
• numbness or coldness in the hands and feet,
• shortness of breath,
• rash, or
• fluid retention in the legs.

Dosage for Bystolic?

The dose of Bystolic is selected individually according to the needs of the patient. For most patients, the recommended starting dose of Bystolic is 5 mg once daily, with or without food, as monotherapy or in combination with other agents.

What drugs, substances or supplements do Bystolic interact with?

Bystolic may interact with cimetidine, clonidine, digitalis, isoniazid, methimazole, reserpine, ropinirole, ticlopidine, other beta-blockers, antibiotics, antidepressants, antimalarials, heart or blood pressure medicines, heart rhythm medicines, HIV medicines, or AIDS or medication to treat mental disorders. Tell your doctor about all medications and supplements you are taking.

Bystolic during pregnancy and lactation

Tell your doctor if you are pregnant or plan to become pregnant while using Bystolic; it is not known if Bystolic will harm the fetus. It is not known if Bystolic passes into breast milk or if it could harm a nursing baby. Consult your doctor before breastfeeding.

More Information

Our Bystolic Side Effects Drug Center provides a comprehensive overview of available drug information about the potential side effects of this medication.

This is not a complete list of side effects and they may occur. Ask your doctor about side effects. You can report side effects to the FDA at 1-800-FDA-1088.

Consumer Information Bystolic Tablets

Get emergency medical help if you have signs of an allergic reaction: hives; labored breathing; swelling of the face, lips, tongue, or throat.

Call your doctor right away if you have:

• feeling dizzy, as if you could pass out;
• rapid weight gain;
• shortness of breath;
• slow or irregular heartbeat; or
• numbness or coldness in hands and feet.

Common side effects may include:

alprazolam 1 mg vs xanax

• dizziness;
• swelling of the legs;
• slow heartbeat;
• fatigue; or
• Headache.

This is not a complete list of side effects and they may occur. Ask your doctor about side effects. You can report side effects to the FDA at 1-800-FDA-1088. bystolic tablets with arterial hypertension and in patients with heart failure. The observed profile of adverse reactions was consistent with the pharmacology of the drug and the health status of patients in clinical trials. Adverse reactions reported for each of these patient groups are presented below. Excluded are adverse reactions that are considered too general to be informative, and adverse reactions that have not been reasonably associated with the use of the drug, because they were associated with the disease being treated or very common in the population receiving treatment.

The data below reflect the worldwide exposure of BYSTOLIC to 6545 patients, including 5038 patients treated for hypertension and the remaining 1507 patients treated for other cardiovascular conditions. Doses ranged from 0.5 mg to 40 mg. Patients received BYSTOLIC for up to 24 months, more than 1900 patients were treated for at least 6 months and approximately 1300 patients for more than one year.

HYPERTENSION

In placebo-controlled clinical trials comparing BISTOLIC with placebo, discontinuation due to adverse reactions was reported in 2. 8% of patients treated with nebivolol and 2.2% of patients treated with placebo. The most common adverse reactions that led to the discontinuation of BYSTOLIC were headache (0.4%), nausea (0.2%) and bradycardia (0.2%).

Table 1 lists treatment-related adverse reactions reported in three 12-week placebo-controlled monotherapy studies in 1597 hypertensive patients treated with BYSTOLIC 5 mg, 10 mg, or 20-40 mg and 205 placebo-treated patients for whom the incidence was at least 1% of patients treated with nebivolol and exceeded the incidence of placebo treatment in at least one dose group.

Table 1: Adverse reactions occurring after treatment, with a frequency (more than 6 weeks) & ge; 1% in patients treated with BYSTOLIC and at a higher frequency than in patients treated with placebo

9015 8

9015 8

reported adverse reactions with a frequency of at least 1% in more than 4300 patients who received BYSTOLIC in controlled or open studies for With the exception of those already listed in Table 1, the terms are too general to be informative, minor symptoms, or adverse reactions that are unlikely to be associated with the drug, as they are common in the population. These adverse reactions in most cases were observed with the same frequency in patients receiving placebo in controlled studies.

Body as a whole: asthenia.

Diseases of the gastrointestinal tract: abdominal pain

Metabolic and nutritional disorders: hypercholesterolemia

Diseases of the nervous system: paresthesia

La boratory abnormalities

In controlled monotherapy trials in patients with hypertension, BYSTOLIC was associated with an increase in BUN, uric acid, triglycerides and a decrease in HDL cholesterol and platelet count.

Post-marketing experience

The following adverse reactions have been identified from spontaneous reports of BYSTOLIC worldwide and have not been listed elsewhere. These adverse reactions were selected for inclusion due to a combination of severity, frequency of reporting, or potential causal association with BYSTOLIC. Adverse reactions specific to the population are usually not mentioned. Because these adverse reactions have been reported voluntarily in a population of uncertain size, it is not possible to estimate their frequency or establish a causal relationship with BYSTOLIC exposure: hepatic impairment (including elevation of AST, ALT and bilirubin), acute pulmonary edema, acute renal failure, atrioventricular block (second and third degree), bronchospasm, erectile dysfunction, hypersensitivity (including urticaria, allergic vasculitis, and rare reports of angioedema), hypotension, myocardial infarction, pruritus, psoriasis, Raynaud’s phenomenon, peripheral ischemia / lameness, syncope, thrombocytopenia, various rashes and skin sickness, dizziness and vomiting.

Read all FDA Prescribing Information for Bystolic Tablets (Nebivolol Tablets)

Read More’ Related Resources for Bystolic Tablets

Associated Health

• Treating High Blood Pressure (Natural Home Remedies, Diet, Medications)

Concomitant drugs

• Attack
• Atakand HCT
• Bumex
• Caduet
• Cardizem LA
• Cardura 9Hct 9 0004
• Lotrel
• Norvasc
• Zebeta

Read Bystolic Tablets User Reviews»

Tablets is provided by Cerner Multum, Inc. and Bystolic Tablets consumer information is provided by First Databank, Inc., used under license and subject to their respective copyrights.

Everything you need to know about beta blockers – Drink-Drink

07/07/2022 DrinkDrinkAdmin

Contents

• What are beta blockers?
• Types of beta blockers and how they work
• What are beta blockers used for?
• Side effects
• Interactions and warnings
• Can beta-blockers be stopped?
• Conclusion

What are beta-blockers?

Beta-blockers are a class of drugs used to block the effects of stress hormones such as adrenaline on the heart. They are often prescribed for irregular heartbeats, high blood pressure, and after heart attacks.

Less commonly, beta-blockers may be used to treat:

• glaucoma
• migraine
• anxiety disorders
• hyperthyroidism
• tremor

90 020 Doctors usually turn to beta-blockers for high blood pressure when other medications such as diuretics do not work or have too many side effects.

Beta blockers may be used with other blood pressure medications, including ACE inhibitors and calcium channel blockers.

Beta-blockers have been shown to have some health benefits beyond helping the heart. For example, they protect bones by preventing the kidneys from excreting calcium in the urine and block stress hormones that could otherwise cause bone thinning over time.

Types of beta blockers and how they work

Because of the way they work in the body, beta blockers are also called beta blockers.

Different types of beta blockers work differently. Generally, these medicines improve the ability of the heart to relax. Your heart will beat slower and less strongly when beta blockers are working. It can help lower blood pressure and alleviate irregular heart rhythms.

Some beta-blockers affect only the heart itself, others affect the heart and blood vessels.

Your doctor may prescribe beta-blockers even if you have few symptoms of heart problems or heart failure. These medications can actually improve the heart’s ability to beat. Acebutolol (Sektral)0004

90 007

Beta-blockers are available in a variety of forms and routes of administration, including oral, intravenous and ophthalmic.

Beta-blockers are usually taken once or twice a day with meals and should usually be taken at the same time each day.

Always take your medicines as directed. Tell your doctor if you have any side effects. You should not stop taking a beta-blocker without first talking to your doctor.

What are beta-blockers used for?

Beta-blockers are used to decrease heart rate and lower blood pressure. They do this by preventing the hormone adrenaline, as well as other stress hormones, from binding to beta receptors throughout the body.

Beta blockers FDA approved for heart disease and blood pressure, including:

• tachycardia
• high blood pressure (hypertension)
• heart attack (myocardial infarction)
• chronic heart failure
• cardiac arrhythmia
• coronary artery disease

9000 9 overactive thyroid (hyperthyroidism)

• essential tremor
• aortic dissection
• portal hypertension

Beta-blockers are sometimes prescribed off-label by doctors for other conditions, including:

• glaucoma
• migraine
• anxiety disorders
• hyperthyroidism
• tremor

Side effects

Side effects these drugs may be different. Many people will experience:

• fatigue
• cold hands
• headache
• digestive problems
• constipation
• diarrhea
• dizziness 9000 4

Rarely, you may experience:

• shortness of breath
• trouble sleeping
• Decreased libido
• Depression

If you accidentally take a higher dose than recommended, you may experience:

• shortness of breath
• changes in vision
• dizziness
• arrhythmia
• confusion

If you know you have overdosed, call your doctor or local poison control center. US National Poison Center phone number: 800-222-1222.

Some older beta blockers such as atenolol and metoprolol have been reported to cause weight gain. Fluid retention and associated weight gain may be signs of heart failure or worsening heart failure.

Be sure to tell your doctor if you gain more than 2-3 pounds in a day, gain more than 5 pounds in a week, or your symptoms get worse.

You may also notice some changes in how your heart works in your daily life. For example, beta-blockers prevent heart rate spikes. You may notice that your heart rate does not rise as high as it normally does during exercise.

Talk to your doctor if you are concerned about your exercise while taking this medicine. They may recommend a stress test to determine your target heart rate during cardio.

Stress tests can also help your doctor determine how hard you work during your workout. This is known as the perceived load level.

Interactions and warnings

Other medicines may increase or decrease the effect of beta-blockers, so be sure to tell your doctor about all medicines, vitamins, and herbal supplements you are taking.

Beta-blockers may interact with drugs such as:

• ACE inhibitors
• allergy medicines such as ephedrine, norepinephrine or epinephrine
• alpha-blockers
• anesthetics 90 004
• antiarrhythmic drugs
• antiulcer drugs
• antidepressants
• antihypertensive and antianginal drugs
• asthma drugs
• calcium channel blockers
• digitalis glycosides
• HMG-CoA reductase inhibitors
• inotropic agents
• isoproterenol and dobutamine
• antipsychotics
• non-steroidal anti-inflammatory drugs (NSAIDs)
• oral hypoglycemic drugs
• other drugs for blood pressure
• psychotropic drugs
• reserpine
• rifampicin (also known as rifampicin)
• thyroxine
• warfarin

Beta-blockers should not be used people with:

• history of fluid retention without the use of diuretics
• severe heart failure
• Raynaud’s disease

Historically that beta-blockers are contraindicated in people with asthma, but this group it is safe to use cardioselective beta-blockers, also known as beta-1-selective.